Tacrolimus
- Generic Name
- Tacrolimus
- Brand Names
- Advagraf, Astagraf, Envarsus, Modigraf, Prograf, Protopic, Tacforius
- Drug Type
- Small Molecule
- Chemical Formula
- C44H69NO12
- CAS Number
- 104987-11-3
- Unique Ingredient Identifier
- Y5L2157C4J
- Background
Tacrolimus (also FK-506 or Fujimycin) is an immunosuppressive drug whose main use is after organ transplant to reduce the activity of the patient's immune system and so the risk of organ rejection. It is also used in a topical preparation in the treatment of severe atopic dermatitis, severe refractory uveitis after bone marrow transplants, and the skin condi...
- Indication
Immediate-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. Extended-release formulations of tacrolimus are indicated for the prophylaxis of organ rejection in adult and pediatric ...
- Associated Conditions
- Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Lung Transplant Rejection, Oral Lichen Planus, Psoriasis, Pyoderma Gangrenosum, Rheumatoid Arthritis, Severe Atopic Dermatitis, Vitiligo, Moderate Atopic dermatitis
- Associated Therapies
- -
Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients
- Conditions
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Leiden University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT04701528
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Netherlands
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
- Conditions
- Interventions
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 128
- Registration Number
- NCT04669210
- Locations
- 🇷🇺
National Hematology Research Center, Moscow, Russian Federation
🇷🇺RM Gorbacheva Research Institute, Saint Petersburg, Russian Federation
The New LC-MS/MS Method for Determination of Unbound Tacrolimus in Plasma
- Conditions
- Interventions
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2022-04-22
- Lead Sponsor
- National Science Centre, Poland
- Target Recruit Count
- 380
- Registration Number
- NCT04657562
- Locations
- 🇵🇱
Department of General and Transplant Surgery, Medical University of Warsaw, Warsaw, Poland
Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)
- First Posted Date
- 2020-11-27
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT04645667
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
- Conditions
- Interventions
- First Posted Date
- 2020-11-16
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT04629248
- Locations
- 🇺🇦
Regional Clinical Hospital n.a I.I. Mechnicov, Dnipropetrovsk, Ukraine
🇺🇦Ternopil University Hospital, Ternopil, Kherson Governorate, Ukraine
🇺🇸Nephrotex Research Group, Dallas, Texas, United States
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
- Conditions
- Refractory Malignant Peripheral Nerve Sheath TumorEwing Sarcoma/Peripheral Primitive Neuroectodermal TumorRecurrent NeuroblastomaRecurrent RhabdomyosarcomaRefractory Malignant Solid NeoplasmDesmoplastic Small Round Cell TumorRecurrent Malignant Peripheral Nerve Sheath TumorRefractory Desmoplastic Small Round Cell TumorRecurrent Desmoplastic Small Round Cell TumorRecurrent Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT04530487
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-08-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT04521946
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Enanta Pharmaceuticals, Inc
- Target Recruit Count
- 89
- Registration Number
- NCT04498741
- Locations
- 🇺🇸
Pharmaceutical Research Associates, Inc.,, Lenexa, Kansas, United States
Belatacept in De Novo Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 12
- Registration Number
- NCT04477629
- Locations
- 🇺🇸
NYU Langone Health, New York, New York, United States
🇺🇸Columbia University, New York, New York, United States
Early Use of Long-acting Tacrolimus in Lung Transplant Recipients
- First Posted Date
- 2020-07-14
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT04469842
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.